Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) that has greatly improved the outcome of patients with HER2-positive breast cancer in both the primary and metastatic setting [1–3]. The gene discussed is ERBB2; the disease is breast cancer.